Organisation paid for research Program year 2025 Source: CMS Open Payments

Activmed Practices and Research Inc

Neither a doctor nor a teaching hospital

Research payments

$6,798,051

1,120 payments

Through program year 2025, Activmed Practices and Research Inc is reported as receiving $6,798,051 in research payments, across 1,120 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $40,598 19
2024 Research $965,601 482
2023 Research $838,427 243
2022 Research $581,097 105
2021 Research $320,150 89
2020 Research $1,452,098 61
2019 Research $2,600,080 121

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $2,744,093 154 payments
  2. Incyte Corporation $1,126,983 786 payments
  3. Biogen, Inc. $878,952 14 payments
  4. Ucb SA $731,933 12 payments
  5. GlaxoSmithKline, LLC. $303,885 48 payments
  6. UCB Biosciences Inc. $300,784 4 payments
  7. Amgen Inc. $229,715 15 payments
  8. Boehringer Ingelheim International GmbH $99,507 2 payments
  9. Genentech, Inc. $93,898 15 payments
  10. Eisai Inc. $89,133 21 payments
Studies the money was for Research payments · program years 2019–2025
  1. A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis $784,358 6 payments
  2. A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa $696,266 472 payments
  3. A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis. $373,736 2 payments
  4. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $347,305 7 payments
  5. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata $332,749 16 payments
  6. A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis $300,784 4 payments
  7. A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease $287,101 3 payments
  8. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $261,620 2 payments
  9. A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Para $246,103 25 payments
  10. Effect of Ly3154207 on Cognition in Mild to Moderate Parkinsons Disease Dementia PDD - the Presence Study $215,687 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record